ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,505.22
1.35%
Dow Jones
43,487.83
0.78%
Gold vs US Dollar
2,703.20
0.00%
Brent Oil
80.005
0.00%
Bitcoin
103,754.31
-0.36%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Atea Pharmaceuticals Inc (AVIR) Share Price

AVIR Atea Pharmaceuticals Inc

3.30
-0.03 (-0.90%)
18 Jan 2025 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Atea Pharmaceuticals Inc NASDAQ:AVIR NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   -0.03 -0.90 3.30 3.13 3.50 3.485 3.36 3.4 337,674 01:00:00   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations  -135.96M -1.6097 -2.09 281.26M
 Type  Size  Price  Time  Units 
 20 382 3.30 22:30:17 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore AVIR News
13/01/202512:00GLOBEAtea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference
08/01/202512:00GLOBEAtea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
16/12/202410:00GLOBEAtea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
04/12/202412:00GLOBEAtea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
26/11/202412:00GLOBEAtea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
20/11/202405:15EDGAR2Form EFFECT - Notice of Effectiveness
15/11/202416:00GLOBEAtea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
Period
Draw mode
Data Downloads for AVIR

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Atea Pharmaceuticals Inc Articles

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads